Macrobdellin
Anticoagulant peptide described in the North American medicinal leech Macrobdella decora.
Preclinical / mechanisticLast updated: 2026-05-26 · Reviewed by ASH Editorial Board
Mechanistic Evidence Box
Preclinical / mechanistic- Page type
- Compound profile
- Evidence type
- Anticoagulant peptide described in the North American medicinal leech Macrobdella decora.
- Evidence level
- Mechanistic discussion
- Drug vs leech
- Purified natural compound
- Safety domains
- Bleeding
Clinical translation limit
Macrobdellin is documented mechanistically only; no human evidence. No FDA-approved derivative exists and Macrobdella decora is not the FDA-cleared device species (Hirudo medicinalis / H. verbana).
Molecular Profile
- Category
- Anticoagulant
- Evidence tier
- Preclinical
- Molecular weight
- 6,800 Da
- Source species
- Macrobdella decora
- Discovered
- 2017
Biological Targets
- → thrombin (Factor IIa)
External Resources
Related Anticoagulant Compounds
Hirudin
The most potent natural thrombin inhibitor — and the molecular template for three FDA-approved direct thrombin inhibitor drugs.
Antistasin
Factor Xa inhibitor — prototype molecule that inspired the entire DOAC drug class (rivaroxaban, apixaban).
Ghilanten
Factor Xa inhibitor with anti-metastatic activity in animal cancer models — translational dual-use compound.
Lefaxin
Factor Xa inhibitor with anti-inflammatory properties.